Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O43353
UPID:
RIPK2_HUMAN
Alternative names:
CARD-containing interleukin-1 beta-converting enzyme-associated kinase; RIP-like-interacting CLARP kinase; Receptor-interacting protein 2; Tyrosine-protein kinase RIPK2
Alternative UPACC:
O43353; B7Z748; Q6UWF0
Background:
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2), with alternative names such as CARD-containing interleukin-1 beta-converting enzyme-associated kinase and Tyrosine-protein kinase RIPK2, plays a pivotal role in immune responses. It acts as a crucial effector in NOD1 and NOD2 signaling pathways, leading to the activation of NF-kappa-B, a key transcription factor in immune response, growth control, and apoptosis protection.
Therapeutic significance:
Understanding the role of Receptor-interacting serine/threonine-protein kinase 2 could open doors to potential therapeutic strategies.